(Bloomberg) — Venus MedTech (HangZhou) Inc. is adding fuel to a boom of health-care IPOs in Hong Kong, as investors bet on rising demand from China’s aging population.The Chinese developer of cardiovascular devices began taking orders Tuesday, counting big names including Singapore’s sovereign fund GIC Pte among its cornerstone investors. Venus is seeking as much as $331 million from the sale, with an expected Dec. 10 listing.Health-care initial public offerings have raised $4.4 billion in Hong Kong since January, setting a record for the first 11 months and marking an almost 30% growth over the same period last year, according …read more
Source:: Yahoo Finance
